Clinical Trial Update: Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lisdexamfetamine sulfate for cognitive dysfunction in multiple sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• lisdexamfetamine sulfate (lisdexamfetamine dimesylate)

Snippet

Sponsor: State University of New York at Buffalo | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2022-09-16